Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drug aims to clear Vision-Damaging material in wet AMD

NCT ID NCT07403825

Disease control Sponsor: Biobizkaia Health Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests the drug faricimab (Vabysmo) in 100 people aged 50+ with wet age-related macular degeneration who have a specific type of harmful material under their retina. The goal is to see if the drug can clear that material by week 16. Participants receive injections into the eye, and researchers will track how well the treatment works using advanced imaging.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
faricimab (Vabysmo) injection
What this could lead to
If successful, this could show that faricimab effectively clears harmful material under the retina, potentially improving vision for people with a specific type of wet age-related macular degeneration.
What could go wrong
This is a relatively small, early-phase (Phase 4) study with only 100 participants. Results may not apply to all patients, and not everyone may see improvement. Eye injections carry risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * People aged 50 and over. * Diagnosed with bilateral or unilateral AMD. * Eyes with SHRM and type 2 or mixed (type 1 and 2) neovascular membrane. * Näive eyes treated with Faricimab following SmPC (summary of product characteristic). * They agree to participate in the study and sign the informed consent form. Exclusion Criteria: * Eyes with type 1, aneurysmal type 1 and type 3 MNV. * Eyes with type 2 MNV and other macular diseases (myopia, posterior uveitis, systemic diseases, such as pseudoxanthoma elasticum). * Eyes with ocular media opacity. * Patients with other retinal diseases, such as central serous chorioretinopathy, diabetic retinopathy, retinal vascular occlusion, uveitis, myopic maculopathy or any other retinal disease that could compromise the best-corrected visual acuity and interfere with retinal parameters. * Any neurological condition (including cognitive impairment, stroke, dementia, Parkinson, anxiety or schizophrenia) that, in the opinion of the investigator, would pose a risk to patient's safety or interfere with the assessment, procedures, or completion of the study. * People who are participating or will participate in any type of clinical trial. * Pregnant women. * Breastfeeding women. * Women\* of childbearing potential who are unable or unwilling to use highly effective methods of contraception (bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices) from the start to the end of the study. * Woman of childbearing potential: considered as such if she is postmenarcheal, has not reached a postmenopausal state (≥12 continuous months of amenorrhea with no identified cause other than menopause), or has not undergone surgical sterilization (removal of ovaries and/or uterus).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Macular degeneration, age related are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Macular degeneration, age related

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinica Barraquer

    RECRUITING

    Barcelona, Catalonia, 08021, Spain

  • Hospital Arruzafa

    RECRUITING

    Córdoba, Andalusia, 14012, Spain

  • Hospital Clínico San Carlos

    RECRUITING

    Madrid, Madrid, 28040, Spain

  • Hospital Clínico Universitario de Valladolid

    RECRUITING

    Valladolid, Castille and León, 47003, Spain

  • Hospital General Universitario Valencia

    RECRUITING

    Valencia, Valencia, 46014, Spain

  • Hospital Puerta de Hierro Majadahonda

    RECRUITING

    Majadahonda, Madrid, 28222, Spain

  • Hospital Universitario Basurto

    RECRUITING

    Bilbao, Bizkaia, 48013, Spain

  • Hospital Universitario Nuestra Señora del Perpétuo Socorro

    RECRUITING

    Albacete, Castille-La Mancha, 02006, Spain

  • Instituto Oftalmologico Fernandez-Vega

    RECRUITING

    Oviedo, Principality of Asturias, 33012, Spain

  • Oftalvist Valencia

    RECRUITING

    Burjassot, Valencia, 46100, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.